Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Kerala Ayurveda Ltd (530163)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530163 NSE: Pharmaceuticals & Drugs | Small Cap | Kerala Ayurveda Share Price
₹143.30 -4.45 (-3.01%)
As on 06-Nov'26 16:59
Kerala Ayurveda Ltd (530163)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530163 NSE: Pharmaceuticals & Drugs | Small Cap | Kerala Ayurveda Share Price
₹143.30 -4.45 (-3.01%)
As on 06-Nov'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹196 Cr.
Current Price
₹143.3
52-Week Low / High
₹130 / 405
TTM EPS
₹-19.4
TTM Sales
₹136 Cr.
Book Value per Share
₹3.7
P/E Ratio
0.00
Industry PE
54.1
Price to Book (P/B)
38.83
Higher than its 5-year historical median
Price to Sales (P/S)
1.44
Lower than its 5-year historical median
EV/EBITDA
-21.84
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-905.31%
Underperforms industry median
Return on Capital Employed (ROCE)
-10.38%
Underperforms industry median
Return on Assets (ROA)
-12.74%
Underperforms industry median
Operating Profit Margin
-13.3%
Underperforms industry median
Net Profit Margin
-12.45%
Underperforms industry median
Gross Profit Margin
-8.3%
Underperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
17.6%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
35.61%
Pledged shares (%) of Promoter's holding (%)
20.35%
Reserves
₹-9 Cr.
Equity
₹13.7 Cr.
Face Value
₹10
All Time Low / High
₹1.40 / 625.00
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Kerala Ayurveda Ltd a good quality company?
Kerala Ayurveda Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Kerala Ayurveda Ltd performance compare with that of its Peers?
Revenue growth of Kerala Ayurveda Ltd vs industry peers?
Kerala Ayurveda Ltd revenue CAGR is 9.40%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Kerala Ayurveda Ltd?
Promoters hold 35.61% of the Kerala Ayurveda Ltd, with 20.35% of their stake pledged, indicating high pledge risk.
Stock return of Kerala Ayurveda Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 7.9% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kerala Ayurveda Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 6% | 7% | 5.1% | 3.7% | -0.6% | 10.2% | 9.9% | 5% | -10.4% | -8.8% | - |
| Value Creation Index ⓘ | -0.6 | -0.5 | -0.6 | -0.7 | -1.0 | -0.3 | -0.3 | -0.6 | -1.7 | -1.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 39.6 | 43.8 | 46.5 | 53.7 | 43.2 | 55.8 | 63.3 | 73.1 | 72.7 | 85.5 | 90 |
| Sales YoY Gr. | - | 10.5% | 6.2% | 15.5% | -19.5% | 29.2% | 13.4% | 15.6% | -0.6% | 17.6% | - |
| Adj EPS ⓘ | 2.1 | 2.2 | 0.3 | 0.8 | -4.7 | 0.8 | 0.9 | -0.2 | -12.5 | -19.3 | -17.9 |
| YoY Gr. | - | 4.3% | -86.7% | 186.2% | -665.1% | NA | 2.4% | -125.6% | NA | NA | - |
| BVPS (₹) ⓘ | 14.1 | 16.7 | 12.8 | 11 | 6.7 | 7.8 | 11.1 | 32.6 | 15.7 | 20 | 22.3 |
| Adj Net Profit ⓘ | 2.2 | 2.3 | 0.3 | 0.9 | -5 | 0.9 | 0.9 | -0.3 | -15.1 | -24.5 | -24 |
| Cash Flow from Ops. ⓘ | 1.5 | -10.9 | 9.3 | 4.7 | -0.9 | 8.8 | 9.1 | -4.2 | 1.9 | -25.1 | - |
| Debt/CF from Ops. ⓘ | 33.9 | -6.4 | 6 | 12.3 | -72.3 | 7 | 7 | -14.7 | 29.3 | -2.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8.9% | 14.6% | 10.5% | 17.6% | ||||
| Adj EPS ⓘ | -228% | NA | -382.2% | NA | ||||
| BVPSⓘ | 4% | 24.6% | 21.9% | 27.2% | ||||
| Share Price | 7.9% | 16.3% | -14.2% | -64% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.5 | 14.2 | 2 | 6.2 | -40.1 | 8.4 | 7.1 | -0.9 | -44.7 | -80.1 | -84.8 |
| Op. Profit Mgn % ⓘ | 12.1 | 12.9 | 6.5 | 5.8 | 0.5 | 13.9 | 7.5 | 6.9 | -17 | -26.3 | -25.1 |
| Net Profit Mgn % ⓘ | 5.6 | 5.3 | 0.7 | 1.6 | -11.5 | 1.6 | 1.4 | -0.4 | -20.7 | -28.7 | -27.1 |
| Debt to Equity ⓘ | 3.5 | 3.9 | 4.2 | 5 | 9.4 | 7.4 | 5.5 | 1.6 | 2.9 | 2.8 | - |
| Working Cap Days ⓘ | 432 | 415 | 421 | 329 | 422 | 320 | 283 | 285 | 337 | 340 | 165 |
| Cash Conv. Cycle ⓘ | 99 | 105 | 107 | 94 | 112 | 79 | 72 | 88 | 131 | 133 | -21 |
Valuation of Kerala Ayurveda - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 13.36 | 13.36 | 13.36 | 13.36 | 20.69 | 23.56 | 23.56 | 20.35 | 20.35 | 20.35 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50 | 56 | 62 | 77 | 62 | 80 | 93 | 108 | 120 | 131 |
| Operating Expenses ⓘ + | 43 | 48 | 57 | 69 | 61 | 71 | 91 | 101 | 125 | 149 |
| Operating Profit ⓘ | 7 | 8 | 5 | 7 | 1 | 10 | 3 | 7 | -5 | -17 |
| Operating Profit Margin (%) | 14.4% | 14.5% | 7.8% | 9.6% | 1.4% | 11.9% | 2.8% | 6.3% | -4.0% | -13.3% |
| Other Income ⓘ + | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 14 |
| Interest ⓘ | 1 | 2 | 3 | 2 | 6 | 7 | 5 | 5 | 5 | 8 |
| Depreciation ⓘ | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 |
| Profit Before Tax ⓘ | 4 | 4 | 3 | 5 | -7 | 3 | -1 | 1 | -12 | -16 |
| Tax ⓘ | 1 | 1 | 1 | 0 | -2 | 0 | -0 | 2 | 2 | -0 |
| Profit After Tax | 3 | 3 | 3 | 4 | -5 | 2 | -0 | -1 | -14 | -16 |
| PAT Margin (%) | 6.5% | 5.2% | 4.1% | 5.3% | -7.8% | 3.0% | -0.5% | -0.8% | -11.6% | -12.5% |
| Adjusted EPS (₹) | 2.9 | 2.7 | 2.3 | 3.7 | -4.6 | 2.2 | -0.5 | -1.3 | -11.6 | -13.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 7 | 8 | 4 | 8 | 3 | 6 | 6 | 32 | 3 | 0 | |
| Debt + | 56 | 75 | 62 | 64 | 77 | 70 | 74 | 68 | 64 | 79 | |
| Minority Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | |
| Trade Payables | 3 | 4 | 4 | 7 | 6 | 8 | 8 | 8 | 6 | 10 | |
| Others Liabilities ⓘ | 12 | 14 | 21 | 22 | 26 | 24 | 26 | 30 | 48 | 40 | |
| Total Liabilities ⓘ | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 124 | 132 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 34 | 32 | 33 | 33 | 33 | 44 | 46 | 46 | 47 | 50 | |
| CWIP ⓘ | 6 | 11 | 12 | 14 | 14 | 4 | 7 | 7 | 9 | 8 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 10 | 10 | 12 | 13 | 11 | 12 | 12 | 16 | 13 | 15 | |
| Trade Receivables | 5 | 5 | 7 | 11 | 10 | 13 | 13 | 16 | 19 | 14 | |
| Cash Equivalents | 3 | 7 | 5 | 6 | 19 | 3 | 4 | 23 | 3 | 6 | |
| Others Assets ⓘ | 23 | 37 | 24 | 26 | 27 | 33 | 32 | 34 | 32 | 40 | |
| Total Assets ⓘ | 81 | 103 | 92 | 103 | 114 | 110 | 115 | 141 | 124 | 132 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 4 | -10 | 12 | 5 | 7 | -1 | 10 | 2 | 5 | -24 |
| Cash Flow From Investing Activity ⓘ + | -3 | -3 | -3 | -4 | -1 | -2 | -7 | -1 | -12 | -5 |
| Cash Flow From Financing Activity ⓘ + | 0 | 17 | -12 | 1 | 6 | -13 | -1 | 18 | -9 | 32 |
| Net Cash Flow ⓘ | 1 | 4 | -2 | 2 | 12 | -16 | 2 | 18 | -17 | 3 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 862.54 | 38.72 | 43.39 | 93.9 | -183.03 | 137.66 | -14.76 | -5.44 | -86.43 | N/A |
| ROCE (%) | 8.91 | 8.88 | 7.64 | 9.27 | -0.45 | 12.62 | 6.18 | 6.75 | -8.66 | N/A |
| Asset Turnover Ratio | 0.7 | 0.64 | 0.64 | 0.79 | 0.57 | 0.72 | 0.83 | 0.84 | 0.95 | 1.02 |
| PAT to CFO Conversion(x) | 1.33 | -3.33 | 4 | 1.25 | N/A | -0.5 | N/A | N/A | N/A | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 30.40 | 31.80 | 36.20 | 41.90 | 61.90 | 53.80 | 51.40 | 48.70 | 51 | 46.10 |
| Inventory Days | 53 | 62.40 | 64.70 | 58 | 70.10 | 52.20 | 47.80 | 47.40 | 41.40 | 39.10 |
| Payable Days | 123.70 | 142.10 | 134.70 | 164.30 | 186.10 | 183.20 | 169 | 155.70 | 128.90 | 119.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Kerala Ayurveda Ltd FAQs
The current trading price of Kerala Ayurveda on 06-Nov-2026 16:59 is ₹143.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Nov-2026 the market cap of Kerala Ayurveda stood at ₹195.6 Cr
The latest P/E ratio of Kerala Ayurveda as of 05-Nov-2026 is 0.00.
The latest P/B ratio of Kerala Ayurveda as of 05-Nov-2026 is 6.42.
The 52-week high of Kerala Ayurveda is ₹405.2 and the 52-week low is ₹130.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kerala Ayurveda is ₹90.45 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kerala Ayurveda Ltd is a below average quality company.
The key valuation ratios of Kerala Ayurveda Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kerala Ayurveda Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Kerala Ayurveda Ltd
Kerala Ayurveda Ltd. (KAL) was founded on the banks of river Periyar at Aluva, Kochi, Kerala in 1945 by Late Vaidyan K G K Panicker, the renowned Ayurvedacharya. He was a doyen in Ayurvedic system, a visionary and a mentor. Now, more than half a century later, his inspired creation epitomizes all that is modern and state-of-the-art in Ayurveda. A leading Ayurvedic company today, KAL is backed by advanced technology and highly qualified dedicated staff.
Today Kerala Ayurveda is a major force in healthcare, growing at a spectacular rate -- with new clinics, new market strategies, new products, and new cures. Some of KAL's products are on the verge of being patented. KAL is truly on a mission to be the number one choice in Ayurveda globally.
Kerala Ayurveda has its world class manufacturing facility at Aluva, near Kochi. It also has a Herbarium.
The R&D Division of KAL has a prestigious herbal garden, which is actually a gene pool with more than 1200 species of rare and endangered medicinal plants, collected by conducting extensive surveys. These efforts also include certain hitherto unexplored tribal pockets, which are treasure groves of herbal wealth.
KAL has started its own Ayurvedic training center in view of propagating authentic Ayurveda. The training center, called KAL HRD CENTER is functioning as an annex to KAL Ayurveda Hospital at Aluva, near Kochi in Kerala. The center is easily assessable since it is located about 10 km, from the Nedumbassery International Airport (Cochin).The center is well equipped and conducts various training programme, various training Programs related with Ayurveda are offered by KAL HRD Center.
Publication Division- KAL has set up a publication division to publish Ayurvedic materials. An Ayurvedic quarterly journal named and styled as KAL VAIDYAM is published by this division. The division is designed to publish books, audio and video CDs and tapes on Ayurveda for the public and the scientific community.
Different offerings of the company:
- Classical Medicines- These are formulations manufactured based on the Ayurvedic Formulatory of India. This is developed from 3000 years old scriptures. In KAL they follow the traditional method for manufacturing these products.
- Proprietary Medicines- These medicines are manufactured based on the formulas developed by KAL R&D division. The products are clinically tested by clinical trial, animal trial, etc before being launched in the market.
- Katrasoft- Katrasoft is the technology division of Katra group, a multinational company with diverse business intrests in over 15 domains and investments in over 20 companies. Katrasoft operates as a division of Kerala Ayurveda Limited, one of the oldest names in Ayurveda, which is a listed company owned by Katra group.
- Katra Nursing- Katra Nursing, one of the divisions of Katra Healtcare Pvt.Ltd. is a fast growing healthcare organization centered in Bangalore, India focussed in the training program of CGFNS, NCLEX and IELTS. The primary objective of the organization is to be a one-stop solution provider for nursing fraternity by exploring the best opportunities availble for KAL's nurses.
Achievements/ recognition:
KAL Hospital, Aluva has been accredited with “Green Leaf†certification by Department of Tourism, Government of Kerala, which is the highest classification for outstanding quality of facilities and services.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now